Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis

Wouter J. Plattel, Aurore Bergamasco, Fabrizio Trinchese, Francois Gavini, Nawal Bent-Ennakhil, Athanasios Zomas, Genaro Castillon, Teigna Arredondo-Bisono, Tiffany Cristarella, Yola Moride, Bastian von Tresckow*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)
86 Downloads (Pure)

Abstract

This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results. A total of 32 observational studies reporting on treatment patterns, overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and adverse events were found. After four cycles, a random-effect model yielded pooled ORR and CR rates of 62.6% (95% confidence interval (CI): 56.0-68.9; I-2 = 9.7%) and 32.9% (95% CI, 20.8-46.3, I-2 = 64.8%), respectively. Regarding survival, 1-year, 2-year, and 5-year PFS ranged from 52.1% to 63.2%, 45.2% to 56.2%, and 31.9% to 33.0%, respectively. OS rates were 68.2-82.7%, 58.0-81.9%, and 58.0-62.0%, respectively. Most common adverse events were hematological toxicities (neutropenia: 13.3-23%, anemia: 8.8-39.0%, and thrombocytopenia: 4-4.6%), and grade >= 3 peripheral neuropathy (3.3-7.3%). This study supports the effectiveness and safety of BV in R/R cHL patients in the real-world setting.

Original languageEnglish
Pages (from-to)3320-3332
Number of pages13
JournalLeukemia & lymphoma
Volume62
Issue number14
DOIs
Publication statusPublished - 6-Dec-2021

Keywords

  • Brentuximab vedotin
  • Hodgkin lymphoma
  • effectiveness
  • systematic review
  • meta-analysis
  • STEM-CELL TRANSPLANTATION
  • NAMED PATIENT PROGRAM
  • SINGLE-CENTER
  • ALLOGENEIC TRANSPLANTATION
  • SALVAGE THERAPY
  • PHASE-II
  • EXPERIENCE
  • SURVIVAL
  • OUTCOMES
  • BRIDGE

Cite this